From the Journals

Two-pronged approach needed in alcohol-associated hepatitis


 

FROM THE JOURNAL OF CLINICAL GASTROENTEROLOGY

Multidisciplinary management for optimal outcomes

In a comment, Nancy S. Reau, MD, chair of hepatology, Rush Medical College, Chicago, agreed with the need to address both the risk for hepatic decompensation and AUD, the benefits of multidisciplinary management of patients, and the importance of patient engagement to successful outcomes.

“As hepatologists, we are often best at managing liver disease, but if you don’t also address the alcohol use disorder, the patient will not have the optimal outcome,” she said in an interview. “Most patients with severe AH have cirrhosis, [which] makes longitudinal follow-up imperative.”

“They are at risk for liver complications but also need aggressive nutritional support and management of their addiction,” she said. “As they improve, they can usually continue intensive treatment.”

Akhil Anand, MD, an addiction psychiatrist and co-director of the Multidisciplinary Alcohol Program at the Cleveland Clinic, also noted the increase in cases of alcohol-associated hepatitis from rising alcohol use.

The review “provides a timely, comprehensive, and impartial overview” of how to manage the condition, he said, as well as “how to treat co-occurring alcohol use disorder in this life-threatening situation.”

No funding was declared. The authors report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

No added benefit of time-restricted eating in NAFLD
MDedge Internal Medicine
Refined incidence rate of HCC with alcohol-associated cirrhosis encourages surveillance
MDedge Internal Medicine
Racial disparities not found in chronic hepatitis B treatment initiation
MDedge Internal Medicine
Dried blood spot test validated for HIV, hep B, and hep C
MDedge Internal Medicine
Harnessing ChatGPT to improve liver disease outcomes
MDedge Internal Medicine
Analysis: 40% of information about cirrhosis on TikTok is incorrect
MDedge Internal Medicine
FDA advisory committee votes against approval for NASH drug
MDedge Internal Medicine
‘Exciting time for NASH’ with resmetirom phase 3 results
MDedge Internal Medicine
Liver disease gets new name and diagnostic criteria
MDedge Internal Medicine
Naltrexone is safe and beneficial in AUD with cirrhosis
MDedge Internal Medicine